These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20394139)

  • 1. Through the looking glass: the evolution of erythropoiesis-stimulating agent use.
    Harvey RD; Khuri FR; Kauh JS
    Oncology (Williston Park); 2010 Mar; 24(3):269, 274. PubMed ID: 20394139
    [No Abstract]   [Full Text] [Related]  

  • 2. Lessons learned from the use of ESAs.
    Mortimer JE
    Oncology (Williston Park); 2010 Mar; 24(3):275, 279. PubMed ID: 20394140
    [No Abstract]   [Full Text] [Related]  

  • 3. Anemia in cancer: update on studies of erythropoiesis-stimulating agents.
    Burstein HJ
    J Support Oncol; 2007 Apr; 5(4 Suppl 2):5-26. PubMed ID: 17550053
    [No Abstract]   [Full Text] [Related]  

  • 4. Committee releases new guidelines on the use of erythropoiesis-stimulating agents.
    McBride D
    ONS Connect; 2011 Feb; 26(2):19. PubMed ID: 21388023
    [No Abstract]   [Full Text] [Related]  

  • 5. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
    Steensma DP
    J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
    Gascón P
    Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
    Wauters I; Vansteenkiste J
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin-stimulating agents: new data yield new insights.
    Zitella L
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):36-8. PubMed ID: 18154208
    [No Abstract]   [Full Text] [Related]  

  • 10. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoiesis-stimulating agents in ovarian cancer patients receiving chemotherapy: to treat or not to treat?
    Marchetti C; Palaia I; Benedetti Panici P
    Int J Gynecol Cancer; 2013 Jun; 23(5):783-4. PubMed ID: 23694979
    [No Abstract]   [Full Text] [Related]  

  • 12. Reassessments of ESAs for cancer treatment in the US and Europe.
    Bennett CL; McKoy JM; Henke M; Silver SM; MacDougall IC; Birgegård G; Luminari S; Casadevall N; Schellekens H; Sartor O; Lai SY; Armitage JO
    Oncology (Williston Park); 2010 Mar; 24(3):260-8. PubMed ID: 20394138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP; Loprinzi CL
    J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of anemia in cancer patients.
    Calabrich A; Katz A
    Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing Chemotherapy-Induced Anemia with Erythropoiesis-Stimulating Agents Plus Iron.
    Whitehead L
    Am J Nurs; 2017 May; 117(5):67. PubMed ID: 28448368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Iron deficiency and anemia in oncology].
    Scotté F; Launay-Vacher V; Ray-Coquard I
    Bull Cancer; 2012 May; 99(5):563-70. PubMed ID: 22516641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
    Schiavetto I; Pedrazzoli P; Basilico V; Siena S
    Chemotherapy; 2008; 54(6):417-20. PubMed ID: 18824846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darbepoetin alpha coming of age.
    Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
    Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darbepoetin alfa and history of thromboembolic events.
    Ferretti G; Felici A; Cognetti F
    J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373
    [No Abstract]   [Full Text] [Related]  

  • 20. Should intravenous iron be the standard of care in oncology?
    Auerbach M
    J Clin Oncol; 2008 Apr; 26(10):1579-81. PubMed ID: 18375888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.